Biomorphis Limited Filleted Accounts Cover
Biomorphis Limited
Company No. SC391317
Information for Filing with The Registrar
31 January 2024
Biomorphis Limited Directors Report Registrar
The Director presents his report and the accounts for the year ended 31 January 2024.
Principal activities
The principal activity of the company during the year under review was architectural activities.
Director
The Director who served at any time during the year was as follows:
P.G. Forissier
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
P.G. Forissier
Director
12 September 2024
Biomorphis Limited Balance Sheet Registrar
at
31 January 2024
Company No.
SC391317
Notes
2024
2023
£
£
Fixed assets
Tangible assets
4
1,0034,745
1,0034,745
Current assets
Cash at bank and in hand
1,70911,988
1,70911,988
Creditors: Amount falling due within one year
5
(30,717)
(30,748)
Net current liabilities
(29,008)
(18,760)
Total assets less current liabilities
(28,005)
(14,015)
Net liabilities
(28,005)
(14,015)
Capital and reserves
Called up share capital
1010
Profit and loss account
6
(28,015)
(14,025)
Total equity
(28,005)
(14,015)
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 12 September 2024 and signed on its behalf by:
P.G. Forissier
Director
12 September 2024
Biomorphis Limited Notes to the Accounts Registrar
for the year ended 31 January 2024
1
General information
Biomorphis Limited is a private company limited by shares and incorporated in Scotland.
Its registered number is: SC391317
Its registered office is:
69/5 Dalmeny Street
Edinburgh
Scotland
EH6 8PW
The accounts have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
2
Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Revenue from the sale of goods is recognised when all the following conditions are satisfied:
• the Company has transferred to the buyer the significant risks and rewards of ownership of the
goods;
• the Company retains neither continuing managerial involvement to the degree usually associated
with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the economic benefits associated with the transaction will flow to the Company;
and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed.
Tangible fixed assets and depreciation
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss.
Depreciation is provided at the following annual rates in order to write off the cost or valuation less the estimated residual value of each asset over its estimated useful life:
Plant and machinery
33% Straight Line
Trade and other creditors
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
Foreign currencies
The functional and presentational currency of the company is Sterling. The accounts are rounded to the nearest pound.
Transactions in currencies, other than the functional currency of the Company, are recorded at the rate of exchange on the date the transaction occurred. Monetary items denominated in other currencies are translated at the rate prevailing at the end of the reporting period. all differences are taken to the profit and loss account. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated.
3
Employees
2024
2023
Number
Number
The average monthly number of employees (including directors) during the year was:
11
4
Tangible fixed assets
Plant and machinery
Total
£
£
Cost or revaluation
At 1 February 2023
14,45914,459
At 31 January 2024
14,45914,459
Depreciation
At 1 February 2023
9,7149,714
Charge for the year
3,7423,742
At 31 January 2024
13,45613,456
Net book values
At 31 January 2024
1,0031,003
At 31 January 2023
4,745
4,745
5
Creditors:
amounts falling due within one year
2024
2023
£
£
Trade creditors
5686
Loans from directors
30,66130,661
Accruals and deferred income
-1
30,71730,748
6
Reserves
Profit and loss account - includes all current and prior period retained profits and losses.
Biomorphis LimitedSC39131731 January 202401 February 2023false12 September 2024BTCSoftware AP Solution 2024 11.1.0411.1.04trueSC3913172023-02-012024-01-31SC3913172024-01-31SC3913172023-01-31SC391317core:WithinOneYear2024-01-31SC391317core:WithinOneYear2023-01-31SC391317core:ShareCapital2024-01-31SC391317core:ShareCapital2023-01-31SC391317core:RetainedEarningsAccumulatedLosses2024-01-31SC391317core:RetainedEarningsAccumulatedLosses2023-01-31SC391317countries:UnitedKingdom2023-02-012024-01-31SC391317bus:RegisteredOffice2023-02-012024-01-31SC391317core:PlantMachinery2023-02-012024-01-31SC3913172022-02-012023-01-31SC391317core:PlantMachinery2023-02-01SC3913172023-02-01SC391317core:PlantMachinery2024-01-31SC391317core:RetainedEarningsAccumulatedLosses2023-02-012024-01-31SC391317bus:SmallEntities2023-02-012024-01-31SC391317bus:FullAccounts2023-02-012024-01-31SC391317bus:AuditExempt-NoAccountantsReport2023-02-012024-01-31SC391317bus:Director12023-02-012024-01-31SC391317bus:PrivateLimitedCompanyLtd2023-02-012024-01-31iso4217:GBPxbrli:pure